Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited Fundamental Analysis
Regencell Bioscience Holdings Limited (RGC) shows weak financial fundamentals with a PE ratio of -4063.01, profit margin of 0.00%, and ROE of -61.93%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -33.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze RGC's fundamental strength across five key dimensions:
Efficiency Score
WeakRGC struggles to generate sufficient returns from assets.
Valuation Score
ExcellentRGC trades at attractive valuation levels.
Growth Score
ModerateRGC shows steady but slowing expansion.
Financial Health Score
ExcellentRGC maintains a strong and stable balance sheet.
Profitability Score
WeakRGC struggles to sustain strong margins.
Key Financial Metrics
Is RGC Expensive or Cheap?
P/E Ratio
RGC trades at -4063.01 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, RGC's PEG of -40.63 indicates potential undervaluation.
Price to Book
The market values Regencell Bioscience Holdings Limited at 2996.27 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -4152.09 times EBITDA. This is generally considered low.
How Well Does RGC Make Money?
Net Profit Margin
For every $100 in sales, Regencell Bioscience Holdings Limited keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-61.93 in profit for every $100 of shareholder equity.
ROA
Regencell Bioscience Holdings Limited generates $-62.27 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
RGC converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-4063.01
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-40.63
vs 25 benchmark
P/B Ratio
Price to book value ratio
2996.27
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.11
vs 25 benchmark
Current Ratio
Current assets to current liabilities
7.39
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.62
vs 25 benchmark
ROA
Return on assets percentage
-0.62
vs 25 benchmark
ROCE
Return on capital employed
-0.74
vs 25 benchmark
How RGC Stacks Against Its Sector Peers
| Metric | RGC Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -4063.01 | 29.43 | Better (Cheaper) |
| ROE | -61.93% | 800.00% | Weak |
| Net Margin | 0.00% | -20145.00% (disorted) | Weak |
| Debt/Equity | 0.11 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 7.39 | 4.64 | Strong Liquidity |
| ROA | -62.27% | -17936.00% (disorted) | Weak |
RGC outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Regencell Bioscience Holdings Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-968.89%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-894.31%
Industry Style: Defensive, Growth, Innovation
Declining